Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III (NPTUNE01)

This study has been terminated.
(Due to poor compliance with study drug administration.)
Sponsor:
Collaborator:
Information provided by:
Westat
ClinicalTrials.gov Identifier:
NCT00439569
First received: February 21, 2007
Last updated: August 30, 2010
Last verified: August 2009
Results First Received: January 19, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Spinal Muscular Atrophy Type II
Spinal Muscular Atrophy Type III
Intervention: Drug: sodium phenylbutyrate

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The protocol was open for recruitment between January 31, 2007 and September 23, 2008 at neurology clinics affiliated with university hospitals.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Pre-specified dosage levels of sodium phenylbutyrate (NaPB) were calculated using the modified Fibonacci rule yielding dosage levels of 500, 675, 900 and 1200 mg /kg/day. The selection of 500 mg/kg/day as the initial dosage was based on the recommended dosage of 450 -600 mg/kg/day for the approved indication for urea cycle disorders in children.

Reporting Groups
  Description
Subjects Enrolled Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first 3 subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The next cohort's dosage was determined by the Modified Continual Re-assessment Method (MCRM)approach and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage. Due to the replacement of subjects (4 not completed), more than 3 subjects were enrolled in Cohort 1. Two new subjects were then enrolled in Cohort 2.

Participant Flow for 2 periods

Period 1:   Cohort 1 (500 mg/kg/Day)
    Subjects Enrolled  
STARTED     7  
COMPLETED     3  
NOT COMPLETED     4  
Allergic reaction                 1  
Less than 80% study drug compliance                 3  

Period 2:   Cohort 2 (500 mg/kg/Day)
    Subjects Enrolled  
STARTED     2 [1]
COMPLETED     1  
NOT COMPLETED     1  
Less than 80% study drug compliance                 1  
[1] 2 new subjects in Cohort 2 were enrolled into the study after Cohort 1 completed the study.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Subjects Enrolled (Cohort 1, Cohort 2) Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first 3 subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The next cohort's dosage was determined by the Modified Continual Re-assessment Method (MCRM)approach and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage. Due to the replacement of subjects (4 not completed), more than 3 subjects were enrolled in Cohort 1.

Baseline Measures
    Subjects Enrolled (Cohort 1, Cohort 2)  
Number of Participants  
[units: participants]
  9  
Age, Customized  
[units: Participants]
 
24 - 48 months     5  
49 -96 months     3  
>96 and < 144 months     1  
Gender  
[units: participants]
 
Female     5  
Male     4  
Region of Enrollment  
[units: participants]
 
United States     9  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Dose Limiting Toxicities (DLT)   [ Time Frame: 29 Days ]

2.  Primary:   Survival Motor Neuron (SMN) Messenger Ribonucleic Acid (mRNA)   [ Time Frame: Baseline - 12 weeks ]

3.  Primary:   Survival Motor Neuron (SMN) Protein   [ Time Frame: Baseline - 12 weeks ]

4.  Secondary:   Drug Safety   [ Time Frame: 14 weeks ]

5.  Secondary:   Pharmacokinetic Parameters (Maximum Plasma Concentration)   [ Time Frame: 12 weeks ]

6.  Secondary:   Pharmacokinetic Parameters (Time to Maximum Concentration)   [ Time Frame: 12 weeks ]

7.  Secondary:   Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC))   [ Time Frame: 12 weeks ]

8.  Secondary:   Overall Study Drug Compliance   [ Time Frame: 12 Weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The study was closed early due to poor study drug compliance. The sample size is therefore extremely limited.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: René Gonin, PhD (Math. Stats.)
Organization: Westat
phone: 301-251-1500
e-mail: renegonin@westat.com


No publications provided


Responsible Party: René Gonin, PhD (Math. Stats.), Senior Biostatistician and NPTUNE Principal Investigator, Westat
ClinicalTrials.gov Identifier: NCT00439569     History of Changes
Other Study ID Numbers: N01NS42361_NPTUNE01, HHSN265200423611C
Study First Received: February 21, 2007
Results First Received: January 19, 2010
Last Updated: August 30, 2010
Health Authority: United States: Food and Drug Administration